This MedLibrary.org supplementary page on Alcuronium chloride is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
 |
|
|
Alcuronium chloride
|
|
| Systematic (IUPAC) name | |
| 4,4'-Didemethyl-4,4'-di-propenyltoxiferin-1-dichloride | |
| Identifiers | |
| CAS number | |
| ATC code | M03 |
| PubChem | |
| Chemical data | |
| Formula | C44H50N4O2+2 |
| Mol. mass | 666.894 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Alcuronium is a peripherally acting muscle relaxant in the curare alkaloid family. It is a semi synthetic substance derived from Toxiferine.
Use - Intubation and ventilation
Action - NDMB post synapthis n2 receptor
Dose .2 - .5 mg/kg ivi
Effects CVS- histamine release and blockage of the sympathetic ganglia including adrenal medulla could cause Hypotension
Resp- apnea due to phrenic blockage but bronchoconstriction can occur from the histamine release
CNS- no effect on intraoccular pressure
Autonomic ganglion blockade can cause decrease in gut motility
Kinetics Poor oral absorption
Distribution - 40 % protein bound Volume of Distribution .37l/kg. Does cross placenta ratio .6
Metabolism - not metabolized
Excretion 70 - 90% unchanged in urine 1.3ml/kg/min t1/2 2- 4 hours
Special points Duration of action prolonger in states of low potassium,calcium and protein, also in staes of high magnesium and acidosis . Pharmaceutically incompatible with thiopentone Infusion can casue fixed dilated pupils
External links
- Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K (2002). "Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist.". J Pharmacol Exp Ther 301 (2): 720–8. doi:. PMID 11961078.
- Maass A, Mohr K (1996). "Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors.". Eur J Pharmacol 305 (1-3): 231–4. doi:. PMID 8813558.
- Jakubík J, Tucek S (1994). "Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium.". J Neurochem 63 (5): 1932–40. PMID 7931349.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 9 September 2008, at 13:45.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Alcuronium chloride".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.